Download PDF
Thromb Haemost 1983; 50(04): 797-799
DOI: 10.1055/s-0038-1665315
Original Article
Schattauer GmbH Stuttgart

Fibrinolytic Activity and the Effects of Beta-Pyridylcarbinol (Ronicol) in Patients with Arteriosclerosis Obliterans

L Grodzińska
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
,
M Basista
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
,
A Kȩdzior
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
,
R Korbut
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
,
E Kostka-Trąbka
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
,
R Gryglewski
The Institute of Pharmacology, N. Copernicus Academy of Medicine, Cracow, Poland
› Author Affiliations
Further Information

Publication History

Received 08 March 1983

Accepted 18 August 1983

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Twenty-one patients with arteriosclerosis obliterans of lower extremities were treated with beta-pyridylcarbinol (Ronicol) for five weeks. The long-term therapy with beta-pyridylcarbinol did not influence platelet aggregability. Activation of the fibrinolytic system was observed. This fibrinolytic effect of Ronicol was abolished in patients treated with aspirin. In most cases a slight clinical improvement was seen, manifested by elongation of pain-free walking distance and increased blood flow in affected limbs. It is concluded that the therapeutic effect of Ronicol in humans may be partly mediated by the release of endogenous prostacyclin.

Keywords

Arteriosclerosis obliterans - Platelet aggregation - Fibrinolysis - Aspirin
 

  • References

  • 1 Mund-Hoym WD. Behandlung chronisch arterieller Angiopathien mit Beta-pyridylcarbinol. Ars Medici (Liestal) 1979; 69: 474-484
    PubMedSearch in Google Scholar
  • 2 Laursen B, Gorman J. Studies on fibrinolytic activity in normal persons and in patients with atherosclerotic vascular disease after physical activity and injections of nicotinic acid. Angiology 1970; 21: 486-492
    CrossrefPubMedSearch in Google Scholar
  • 3 Stuart SE. Long acting form of the peripheral vasodilatory nicotinyl alcohol: double-blind evaluation. J Am Geriatr Soc 1976; 15: 780-785
    PubMedSearch in Google Scholar
  • 4 Zöllner N, Gudenzi M. Behandlung der Hypercholesterinämie mit Beta-pyridylcarbinol. Med Klinik 1966; 51: 2036-2040
    PubMedSearch in Google Scholar
  • 5 Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic add on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor. Med Biol 1979; 57: 114-117
    PubMedSearch in Google Scholar
  • 6 Dembińska-Kieć A, Korbut R, Bieron K, Kostka-Trgöka E, Gryg-lewski R. Beta-pyridylcarbinol (Ronicol®) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharm Res Commun 1983; 15: 377-385
    CrossrefPubMedSearch in Google Scholar
  • 7 Whitney RJ. The measurement of volume changes in human limbs. J Physiol 1953; 121: 1-27
    PubMedSearch in Google Scholar
  • 8 Splawiński J, Wojtaszek B, Marcinkiewicz E. Bioassay of thrombo-xane A2by contraction of guinea pig parenchyma lung strip. Thromb Res 1981; 21: 35-44
    CrossrefPubMedSearch in Google Scholar
  • 9 Kaulla von KN, Schultz RL. Methods for evaluation of human fibrinolysis. Am J Clin Path 1958; 29: 104-112
    CrossrefPubMedSearch in Google Scholar
  • 10 Wheithman KU, Granzer E. Stimulation of anti-aggregatory activity from rat aorta by hypolipidemic drugs. Artery 1980; 8: 475-481
    PubMedSearch in Google Scholar
  • 11 Szczeklik A, Gryglewski R. Treatment of vascular disease with prostacyclin. In: Clinical Pharmacology of Prostacyclin. Lewis PJ, O’Grady J. (Eds) Raven Press; New York: 1981. pp 159-168
    Search in Google Scholar
  • 12 Dembińska-Kieć A, Kostka-Trąbka E, Żmuda A, Byrska-Danek A, Bieroń K, Grodzińska L, Kȩdzior A, Żelazny T. Effect of prostacyclin on platelet and fibrinolytic activity in patients with arteriosclerosis obliterans. Pharm Res Commun 1982; 14: 485-498
    CrossrefPubMedSearch in Google Scholar
  • 13 Vincent JE, Zijstra FJ. Nicotinic add inhibits thromboxane synthesis in platelets. Prostaglandins 1978; 15: 628-636
    PubMedSearch in Google Scholar